ImmTAC/Anti-PD-1 antibody combination to enhance killing of cancer cells by reversing regulatory T-cell-mediated immunosuppression-Reference-Cited by-同舟云学术

ImmTAC/Anti-PD-1 antibody combination to enhance killing of cancer cells by reversing regulatory T-cell-mediated immunosuppression

Published:2018-06-14 Issue:2 Volume:155 Page:238-250
ISSN:0019-2805
Container-title:Immunology
language:en
Short-container-title:Immunology

Author:

Zhang Huanling¹²^ORCID,Li Yanyan¹²,Liu Xiaoping²,Liang Zhaoduan²,Yan Mengyong³,Liu Qiang²,Chen Anan²,Bao Yifeng²,Zhou Chengzhi⁴,Li Shiyue⁴,Yee Cassian⁵,Li Yi²³

Affiliation:

1. School of Life Sciences; University of Science and Technology of China; Hefei Anhui China

2. State Key Laboratory of Respiratory Disease; Guangzhou Institutes of Biomedicine and Health; Chinese Academy of Sciences; Guangzhou Guangdong China

3. XiangXue Life Sciences Research Centre; XiangXue Pharmaceutical Co. Ltd; Guangzhou Guangdong China

4. State Key Laboratory of Respiratory Disease; National Clinical Research Centre for Respiratory Disease; Guangzhou Institutes of Respiratory Disease; The First Affiliated Hospital of Guangzhou Medical University; Guangzhou Guangdong China

5. Department of Melanoma Medical Oncology and Department of Immunology; MD Anderson Cancer Center; Houston TX USA

Funder

Guangzhou Science Technology and Innovation Commission Project Grants

The National key R&D Programme

Guangzhou Science and Technology Program key projects

National Natural Science Foundation of China

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/imm.12954/fullpdf